The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA.
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Cancer Cell. 2019 May 13;35(5):721-737.e9. doi: 10.1016/j.ccell.2019.03.014. Epub 2019 May 2.
The mitochondrial caseinolytic protease P (ClpP) plays a central role in mitochondrial protein quality control by degrading misfolded proteins. Using genetic and chemical approaches, we showed that hyperactivation of the protease selectively kills cancer cells, independently of p53 status, by selective degradation of its respiratory chain protein substrates and disrupts mitochondrial structure and function, while it does not affect non-malignant cells. We identified imipridones as potent activators of ClpP. Through biochemical studies and crystallography, we show that imipridones bind ClpP non-covalently and induce proteolysis by diverse structural changes. Imipridones are presently in clinical trials. Our findings suggest a general concept of inducing cancer cell lethality through activation of mitochondrial proteolysis.
线粒体组织蛋白酶 P(ClpP)通过降解错误折叠的蛋白质在线粒体蛋白质量控制中发挥核心作用。我们通过遗传和化学方法表明,蛋白酶的过度激活选择性地杀死癌细胞,而与 p53 状态无关,其通过选择性降解其呼吸链蛋白底物来实现,并破坏线粒体结构和功能,而不影响非恶性细胞。我们发现了 imipridones 是 ClpP 的有效激活剂。通过生化研究和晶体学,我们表明 imipridones 以非共价的方式结合 ClpP,并通过多种结构变化诱导蛋白水解。目前 imipridones 正在进行临床试验。我们的研究结果表明,通过激活线粒体蛋白水解来诱导癌细胞致死具有普遍意义。